Search

Your search keyword '"Krebs, Shelly J"' showing total 284 results
Start Over Author "Krebs, Shelly J"
284 results on '"Krebs, Shelly J"'

1. Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Author

Kim, In-Jeong, Gonzalez, Olga, Tighe, Michael P., Lanthier, Paula A., Clark, Madeline J., Travis, Kelsey L., Low-Beer, Timothy C., Lanzer, Kathleen G., Bernacki, Derek T., Szaba, Frank M., De La Barrera, Rafael A., Dussupt, Vincent, Mendez-Rivera, Letzibeth, Krebs, Shelly J., Ross, Corinna N., Mdaki, Stephanie D., Brasky, Kathleen M., Layne-Colon, Donna, Tardif, Suzette D., Thomas, Stephen J., Modjarrad, Kayvon, Blackman, Marcia A., and Patterson, Jean L.

Published
2024
Full Text
View/download PDF

2. Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice

Author

Kim, In-Jeong, Tighe, Michael P., Lanthier, Paula A., Clark, Madeline J., De La Barrera, Rafael A., Dussupt, Vincent, Mendez-Rivera, Letzibeth, Krebs, Shelly J., Travis, Kelsey L., Low-Beer, Timothy C., Cookenham, Tres S., Lanzer, Kathleen G., Bernacki, Derek T., Szaba, Frank M., Schneck, Amanda A., Ward, Jerrold, Thomas, Stephen J., Modjarrad, Kayvon, and Blackman, Marcia A.

Published
2024
Full Text
View/download PDF

3. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

Author

Sankhala, Rajeshwer S., Lal, Kerri G., Jensen, Jaime L., Dussupt, Vincent, Mendez-Rivera, Letzibeth, Bai, Hongjun, Wieczorek, Lindsay, Mayer, Sandra V., Zemil, Michelle, Wagner, Danielle A., Townsley, Samantha M., Hajduczki, Agnes, Chang, William C., Chen, Wei-Hung, Donofrio, Gina C., Jian, Ningbo, King, Hannah A. D., Lorang, Cynthia G., Martinez, Elizabeth J., Rees, Phyllis A., Peterson, Caroline E., Schmidt, Fabian, Hart, Tricia J., Duso, Debra K., Kummer, Lawrence W., Casey, Sean P., Williams, Jazmean K., Kannan, Shruthi, Slike, Bonnie M., Smith, Lauren, Swafford, Isabella, Thomas, Paul V., Tran, Ursula, Currier, Jeffrey R., Bolton, Diane L., Davidson, Edgar, Doranz, Benjamin J., Hatziioannou, Theodora, Bieniasz, Paul D., Paquin-Proulx, Dominic, Reiley, William W., Rolland, Morgane, Sullivan, Nancy J., Vasan, Sandhya, Collins, Natalie D., Modjarrad, Kayvon, Gromowski, Gregory D., Polonis, Victoria R., Michael, Nelson L., Krebs, Shelly J., and Joyce, M. Gordon

Published
2024
Full Text
View/download PDF

4. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption

Author

Mdluli, Thembi, Slike, Bonnie M., Curtis, Daniel J., Shubin, Zhanna, Tran, Ursula, Li, Yifan, Dussupt, Vincent, Mendez-Rivera, Letzibeth, Pinyakorn, Suteeraporn, Stieh, Daniel J., Tomaka, Frank L., Schuitemaker, Hanneke, Pau, Maria G., Colby, Donn J., Kroon, Eugène, Sacdalan, Carlo, de Souza, Mark, Phanupak, Nittaya, Hsu, Denise C., Ananworanich, Jintanat, Ake, Julie A., Trautmann, Lydie, Vasan, Sandhya, Robb, Merlin L., Krebs, Shelly J., Paquin-Proulx, Dominic, and Rolland, Morgane

Published
2024
Full Text
View/download PDF

5. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

Author

Gebrehana, Beza, Greenleaf, Melissa E, Hamer, Melinda J, Jansen, Nathan K, Jing, Xiaotang, Kagai, Jael, Kourbanova, Kamila, Koren, Michael A, Martin, Monica L, Wuertz, Kathryn McGuckin, Regules, Jason A, Sanborn, Aaron D, Wallace, David, Zhu, Lei, Gromowski, Gregory D, Corbitt, Courtney, Darden, Janice M, Dussupt, Vincent, Golub, Emily S, Headley, Jarrett A, Jarral, Umair M, King, Jocelyn, Krebs, Shelly J, Lay, Jenny, Lilly, Regina, Lynch, Jennifer, Martinez, Elizabeth J, Mayer, Sandra V, McGeehon, Samantha, Lee, Hyunna, Schech, Steven, Tadesse, Mekdi, Thomas, Paul V, Romem, Yahel, Zografos, Erifile, Lin, Bob C, Narpala, Sandeep R, Wang, Lingshu, Doria-Rose, Nicole A, Carroll, Robin E, Eaton, Amanda, Badraslioglu, Emily D, Koontz, Jason M, Nwaeze, Ugo E, Dawson, Peter, Noll, Alexander J, Orndahl, Christine M, Bray, Amy, Carrion, Ricardo, Jr., Patterson, Jean, Kulkarni, Viraj, Hallam, Cory, Gonzalez, Olga, Gazi, Michal, Ober Shepherd, Brittany L, Scott, Paul T, Hutter, Jack N, Lee, Christine, McCauley, Melanie D, Guzman, Ivelese, Bryant, Christopher, McGuire, Sarah, Kennedy, Jessie, Chen, Wei-Hung, Hajduczki, Agnes, Mdluli, Thembi, Valencia-Ruiz, Anais, Amare, Mihret F, Matyas, Gary R, Rao, Mangala, Rolland, Morgane, Mascola, John R, De Rosa, Stephen C, McElrath, M Juliana, Montefiori, David C, Serebryannyy, Leonid, McDermott, Adrian B, Peel, Sheila A, Collins, Natalie D, Joyce, M Gordon, Robb, Merlin L, Michael, Nelson L, Vasan, Sandhya, and Modjarrad, Kayvon

Published
2024
Full Text
View/download PDF

6. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity

Author

Chen, Wei-Hung, Hajduczki, Agnes, Martinez, Elizabeth J., Bai, Hongjun, Matz, Hanover, Hill, Thomas M., Lewitus, Eric, Chang, William C., Dawit, Layla, Peterson, Caroline E., Rees, Phyllis A., Ajayi, Adelola B., Golub, Emily S., Swafford, Isabella, Dussupt, Vincent, David, Sapna, Mayer, Sandra V., Soman, Sandrine, Kuklis, Caitlin, Corbitt, Courtney, King, Jocelyn, Choe, Misook, Sankhala, Rajeshwer S., Thomas, Paul V., Zemil, Michelle, Wieczorek, Lindsay, Hart, Tricia, Duso, Debora, Kummer, Larry, Yan, Lianying, Sterling, Spencer L., Laing, Eric D., Broder, Christopher C., Williams, Jazmean K., Davidson, Edgar, Doranz, Benjamin J., Krebs, Shelly J., Polonis, Victoria R., Paquin-Proulx, Dominic, Rolland, Morgane, Reiley, William W., Gromowski, Gregory D., Modjarrad, Kayvon, Dooley, Helen, and Joyce, M. Gordon

Published
2023
Full Text
View/download PDF

7. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain

Author

Sankhala, Rajeshwer S., Dussupt, Vincent, Chen, Wei-Hung, Bai, Hongjun, Martinez, Elizabeth J., Jensen, Jaime L., Rees, Phyllis A., Hajduczki, Agnes, Chang, William C., Choe, Misook, Yan, Lianying, Sterling, Spencer L., Swafford, Isabella, Kuklis, Caitlin, Soman, Sandrine, King, Jocelyn, Corbitt, Courtney, Zemil, Michelle, Peterson, Caroline E., Mendez-Rivera, Letzibeth, Townsley, Samantha M., Donofrio, Gina C., Lal, Kerri G., Tran, Ursula, Green, Ethan C., Smith, Clayton, de Val, Natalia, Laing, Eric D., Broder, Christopher C., Currier, Jeffrey R., Gromowski, Gregory D., Wieczorek, Lindsay, Rolland, Morgane, Paquin-Proulx, Dominic, van Dyk, Dewald, Britton, Zachary, Rajan, Saravanan, Loo, Yueh Ming, McTamney, Patrick M., Esser, Mark T., Polonis, Victoria R., Michael, Nelson L., Krebs, Shelly J., Modjarrad, Kayvon, and Joyce, M. Gordon

Published
2024
Full Text
View/download PDF

9. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine

Author

Li, Yifan, Merbah, Mélanie, Wollen-Roberts, Suzanne, Beckman, Bradley, Mdluli, Thembi, Curtis, Daniel J., Currier, Jeffrey R., Mendez-Rivera, Letzibeth, Dussupt, Vincent, Krebs, Shelly J., De La Barrera, Rafael, Michael, Nelson L., Paquin-Proulx, Dominic, Eller, Michael A., Koren, Michael A., Modjarrad, Kayvon, and Rolland, Morgane

Published
2023
Full Text
View/download PDF

10. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

Author

Koren, Michael A, Lin, Leyi, Eckels, Kenneth H, De La Barrera, Rafael, Dussupt, Vincent, Donofrio, Gina, Sondergaard, Erica L, Mills, Kristin T, Robb, Merlin L, Lee, Christine, Adedeji, Oluwaseun, Keiser, Paul B, Curley, Justin M, Copeland, Nathanial K, Crowell, Trevor A, Hutter, Jack N, Hamer, Melinda J, Valencia-Ruiz, Anais, Darden, Janice, Peel, Sheila, Amare, Mihret F, Mebrahtu, Tsedal, Costanzo, Margaret, Krebs, Shelly J, Gromowski, Gregory D, Jarman, Richard G, Thomas, Stephen J, Michael, Nelson L, and Modjarrad, Kayvon

Published
2023
Full Text
View/download PDF

11. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

Author

Sankhala, Rajeshwer S., Dussupt, Vincent, Donofrio, Gina, Gromowski, Gregory D., De La Barrera, Rafael A., Larocca, Rafael A., Mendez-Rivera, Letzibeth, Lee, Anna, Choe, Misook, Zaky, Weam, Mantus, Grace, Jensen, Jaime L., Chen, Wei-Hung, Gohain, Neelakshi, Bai, Hongjun, McCracken, Michael K., Mason, Rosemarie D., Leggat, David, Slike, Bonnie M., Tran, Ursula, Jian, Ningbo, Abbink, Peter, Peterson, Rebecca, Mendes, Erica Araujo, Freitas de Oliveira Franca, Rafael, Calvet, Guilherme Amaral, Bispo de Filippis, Ana Maria, McDermott, Adrian, Roederer, Mario, Hernandez, Mayda, Albertus, Amie, Davidson, Edgar, Doranz, Benjamin J., Rolland, Morgane, Robb, Merlin L., Lynch, Rebecca M., Barouch, Dan H., Jarman, Richard G., Thomas, Stephen J., Modjarrad, Kayvon, Michael, Nelson L., Krebs, Shelly J., and Joyce, M. Gordon

Published
2023
Full Text
View/download PDF

12. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.

Author

Lal, Kerri G, Kim, Dohoon, Costanzo, Margaret C, Creegan, Matthew, Leeansyah, Edwin, Dias, Joana, Paquin-Proulx, Dominic, Eller, Leigh Anne, Schuetz, Alexandra, Phuang-Ngern, Yuwadee, Krebs, Shelly J, Slike, Bonnie M, Kibuuka, Hannah, Maganga, Lucas, Nitayaphan, Sorachai, Kosgei, Josphat, Sacdalan, Carlo, Ananworanich, Jintanat, Bolton, Diane L, Michael, Nelson L, Shacklett, Barbara L, Robb, Merlin L, Eller, Michael A, and Sandberg, Johan K

Abstract

Mucosa-associated invariant T (MAIT) cell loss in chronic HIV-1 infection is a significant insult to antimicrobial immune defenses. Here we investigate the response of MAIT cells during acute HIV-1 infection utilizing the RV217 cohort with paired longitudinal pre- and post-infection samples. MAIT cells are activated and expand in blood and mucosa coincident with peak HIV-1 viremia, in a manner associated with emerging microbial translocation. This is followed by a phase with elevated function as viral replication is controlled to a set-point level, and later by their functional decline at the onset of chronic infection. Interestingly, enhanced innate-like pathways and characteristics develop progressively in MAIT cells during infection, in parallel with TCR repertoire alterations. These findings delineate the dynamic MAIT cell response to acute HIV-1 infection, and show how the MAIT compartment initially responds and expands with enhanced function, followed by progressive reprogramming away from TCR-dependent antibacterial responses towards innate-like functionality.

Published
2020

13. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection

Author

Peluso, Michael J, Colby, Donn J, Pinyakorn, Suteeraporn, Ubolyam, Sasiwimol, Intasan, Jintana, Trichavaroj, Rapee, Chomchey, Nitiya, Prueksakaew, Peeriya, Slike, Bonnie M, Krebs, Shelly J, Jian, Ningbo, Robb, Merlin L, Phanuphak, Praphan, Phanuphak, Nittaya, Spudich, Serena, Ananworanich, Jintanat, Kroon, Eugène, Teeratakulpisarn, Nipat, Pattanachaiwit, Supanit, Sacdalan, Carlo, Sriplienchan, Somchai, de Souza, Mark, Tantivitayakul, Ponpen, Poltavee, Kultida, Luekasemsuk, Tassanee, Savadsuk, Hathairat, Tipsuk, Somporn, Puttamsawin, Suwanna, Benjapornpong, Khunthalee, Ratnaratorn, Nisakorn, Tangnaree, Kamonkan, Munkong, Chutharat, Thaimanee, Rommanus, Eamyoung, Patcharin, Buranapraditkun, Supranee, Lerdlum, Sukalya, Manasnayakorn, Sopark, Rerknimitr, Rugsun, Sirivichayakul, Sunee, Wattanaboonyongcharoen, Phandee, Suttichom, Duanghathai, O'Connell, Robert, Schuetz, Alexandra, Hsu, Denise, Akapirat, Siriwat, Nuntapinit, Bessara, Tantibul, Nantana, Churikanont, Nampueng, Getchalarat, Saowanit, Michael, Nelson, Vasan, Sandhya, Crowell, Trevor, Turk, Ellen, McCullough, Corinne, Butterworth, Oratai, Milazzo, Mark, and Anne Eller, Leigh

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Digestive Diseases, Clinical Research, Infectious Diseases, Liver Disease, HIV/AIDS, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Adult, Alanine Transaminase, Alkynes, Benzoxazines, Cohort Studies, Cyclopropanes, Female, HIV Infections, Humans, Liver Diseases, Liver Function Tests, Male, Thailand, Young Adult, HIV, acute HIV, liver function tests, Acquired Immunodeficiency Syndrome, antiretroviral agents, anti-HIV agents, SEARCH010/RV254 Study Group, Public Health and Health Services, Other Medical and Health Sciences, Clinical sciences, Epidemiology, Public health
Abstract

IntroductionLiver disease is a common cause of non-AIDS morbidity and mortality in people living with HIV (PLHIV), but the prevalence and significance of liver function test (LFT) abnormalities in early HIV infection is unknown. This study aimed to characterize LFTs in a large cohort of participants with acute HIV infection initiating immediate antiretroviral therapy (ART) and examine the association between LFTs and biomarkers of HIV infection and inflammation.MethodsWe measured LFTs at the time of HIV diagnosis and at 4, 12, 24 and 48 weeks after ART initiation in 426 Thai individuals with acute HIV infection from 2009 to 2018. A subset of individuals had data available at 96 and 144 weeks. We excluded individuals with concomitant viral hepatitis. Alanine aminotransferase (ALT) was the primary outcome of interest; values greater than 1.25 times the upper limit of normal were considered elevated. Analyses utilized descriptive statistics, non-parametric tests and multivariate logistic regression.ResultsSixty-six of the 426 individuals (15.5%) had abnormal baseline ALT levels; the majority (43/66, 65.5%) had Grade 1 elevations. Elevated baseline ALT correlated with Fiebig stages III to V (p = 0.001) and baseline HIV RNA >6 log10 copies/mL (p = 0.012). Baseline elevations resolved by 48 weeks on ART in 59 of the 66 individuals (89%). ALT elevations at 24 and 48 weeks correlated with Fiebig stages I to II at diagnosis (p 350 cells/μL (p = 0.03) and older age (p = 0.03). Individuals initiating efavirenz-based regimens were more likely to have elevated ALT levels at 48 weeks compared with those on non-efavirenz-based regimens (p = 0.003).ConclusionsOne in six people with acute HIV infection have elevated LFTs. Clinical outcomes with ART started in acute HIV are generally good, with resolution of ALT elevations within 48 weeks on ART in most cases. These results suggest a multifactorial model for hepatic injury involving a combination of HIV-associated and ART-associated processes, which may change over time.

Published
2020

14. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma

Author

Hellmuth, Joanna, Slike, Bonnie M, Sacdalan, Carlo, Best, John, Kroon, Eugene, Phanuphak, Nittaya, Fletcher, James LK, Prueksakaew, Peeriya, Jagodzinski, Linda L, Valcour, Victor, Robb, Merlin, Ananworanich, Jintanat, Allen, Isabel E, Krebs, Shelly J, and Spudich, Serena

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, HIV/AIDS, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Infection, Acute Disease, Adult, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Biomarkers, CD4 Lymphocyte Count, CD4-CD8 Ratio, Cohort Studies, Female, HIV Infections, HIV-1, Host-Pathogen Interactions, Humans, Lymphocyte Activation, Male, RNA, Viral, Time-to-Treatment, Viral Load, Young Adult, CSF, immune activation, acute HIV, inflammation, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundChronic immune activation in the blood and central nervous system is a consequence of human immunodeficiency virus (HIV) infection that contributes to disease morbidity and can occur despite virally suppressive antiretroviral therapy (ART). The trajectory of HIV-related inflammation may vary with the timing of ART initiation. We examined immune activation markers in cerebrospinal fluid (CSF) and blood specimens collected over 96 weeks from participants who initiated ART during acute HIV infection (AHI).MethodsRV254/SEARCH010 study participants with AHI underwent CSF (n = 89) and plasma (n = 146) sampling before initiating ART and at weeks 24 and 96 of treatment. A majority participants (64.4%) received a standard ART regimen (hereafter, "standard ART"), with some (34.7%) also receiving maraviroc and raltegravir for the first 24 weeks (hereafter, "ART plus"). We compared neopterin, CXCL10, CCL2, and interleukin 6 (IL-6) levels in the AHI group to those in 18 healthy, uninfected controls.ResultsFollowing 24 and 96 weeks of treatment, levels of all CSF markers normalized while levels of several plasma markers remained elevated in the AHI group (P < .001). Participants receiving the ART-plus regimen had lower median plasma CCL2 levels at week 24 and lower plasma neopterin levels at week 96.ConclusionsART initiation during AHI differentially impacts the brain compartment, with markers of inflammation returning to normal levels in the CSF, where they were sustained at week 96, but not in plasma.

Published
2019

15. Preferential and persistent impact of acute HIV-1 infection on CD4⁺ iNKT cells in colonic mucosa

Author

RV217, RV254/SEARCH010, RV304/SEARCH013 StudyGroup, Paquin-Proulx, Dominic, Lal, Kerri G., Phuang-Ngern, Yuwadee, Creegan, Matthew, Tokarev, Andrey, Suhkumvittay, Suchada, Alrubayyi, Aljawharah, Kroon, Eugène, Pinyakorn, Suteeraporn, Slike, Bonnie M., Bolton, Diane L., Krebs, Shelly J., Eller, Leigh Anne, Sajjaweerawan, Chayada, Pagliuzza, Amélie, Chomont, Nicolas, Rerknimitr, Rungsun, Chomchey, Nitiya, Phanuphak, Nittaya, de Souza, Mark S., Michael, Nelson L., Robb, Merlin L., Ananworanich, Jintanat, Sandberg, Johan K., Eller, Michael A., and Schuetz, Alexandra

Published
2021

16. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium

Author

Callaway, Heather M., Hastie, Kathryn M., Schendel, Sharon L., Li, Haoyang, Yu, Xiaoying, Shek, Jeremy, Buck, Tierra, Hui, Sean, Bedinger, Dan, Troup, Camille, Dennison, S. Moses, Li, Kan, Alpert, Michael D., Bailey, Charles C., Benzeno, Sharon, Bonnevier, Jody L., Chen, Jin-Qiu, Chen, Charm, Cho, Hyeseon, Crompton, Peter D., Dussupt, Vincent, Entzminger, Kevin C., Ezzyat, Yassine, Fleming, Jonathan K., Geukens, Nick, Gilbert, Amy E., Guan, Yongjun, Han, Xiaojian, Harvey, Christopher J., Hatler, Julia M., Howie, Bryan, Hu, Chao, Huang, Ailong, Imbrechts, Maya, Jin, Aishun, Kamachi, Nik, Keitany, Gladys, Klinger, Mark, Kolls, Jay K., Krebs, Shelly J., Li, Tingting, Luo, Feiyan, Maruyama, Toshiaki, Meehl, Michael A., Mendez-Rivera, Letzibeth, Musa, Andrea, Okumura, C.J., Rubin, Benjamin E.R., Sato, Aaron K., Shen, Meiying, Singh, Anirudh, Song, Shuyi, Tan, Joshua, Trimarchi, Jeffrey M., Upadhyay, Dhruvkumar P., Wang, Yingming, Yu, Lei, Yuan, Tom Z., Yusko, Erik, Peters, Bjoern, Tomaras, Georgia, and Saphire, Erica Ollmann

Published
2023
Full Text
View/download PDF

17. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

Author

King, Hannah A. D., Joyce, M. Gordon, Lakhal-Naouar, Ines, Ahmed, Aslaa, Cincotta, Camila Macedo, Subra, Caroline, Peachman, Kristina K., Hack, Holly R., Chen, Rita E., Thomas, Paul V., Chen, Wei-Hung, Sankhala, Rajeshwer S., Hajduczki, Agnes, Martinez, Elizabeth J., Peterson, Caroline E., Chang, William C., Choe, Misook, Smith, Clayton, Headley, Jarrett A., Elyard, Hanne A., Cook, Anthony, Anderson, Alexander, Wuertz, Kathryn McGuckin, Dong, Ming, Swafford, Isabella, Case, James B., Currier, Jeffrey R., Lal, Kerri G., Amare, Mihret F., Dussupt, Vincent, Molnar, Sebastian, Daye, Sharon P., Zeng, Xiankun, Barkei, Erica K., Alfson, Kendra, Staples, Hilary M., Carrion, Ricardo, Krebs, Shelly J., Paquin-Proulx, Dominic, Karasavvas, Nicos, Polonis, Victoria R., Jagodzinski, Linda L., Vasan, Sandhya, Scott, Paul T., Huang, Yaoxing, Nair, Manoj S., Ho, David D., de Val, Natalia, Diamond, Michael S., Lewisi, Mark G., Rao, Mangala, Matyas, Gary R., Gromowski, Gregory D., Peel, Sheila A., Michael, Nelson L., Modjarrad, Kayvon, and Bolton, Diane L.

Published
2021

18. Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding

Author

Bai, Hongjun, primary, Lewitus, Eric, additional, Li, Yifan, additional, Thomas, Paul V., additional, Zemil, Michelle, additional, Merbah, Mélanie, additional, Peterson, Caroline E., additional, Thuraisamy, Thujitha, additional, Rees, Phyllis A., additional, Hajduczki, Agnes, additional, Dussupt, Vincent, additional, Slike, Bonnie, additional, Mendez-Rivera, Letzibeth, additional, Schmid, Annika, additional, Kavusak, Erin, additional, Rao, Mekhala, additional, Smith, Gabriel, additional, Frey, Jessica, additional, Sims, Alicea, additional, Wieczorek, Lindsay, additional, Polonis, Victoria, additional, Krebs, Shelly J., additional, Ake, Julie A., additional, Vasan, Sandhya, additional, Bolton, Diane L., additional, Joyce, M. Gordon, additional, Townsley, Samantha, additional, and Rolland, Morgane, additional

Published
2024
Full Text
View/download PDF

19. Informing the Need for a SARS-CoV-2 Booster Based Upon the Immune Responses among Young Healthy Adults to Variants Circulating in Late 2023

Author

Nguyen, Huy C, primary, Lal, Kerri G, additional, Balinsky, Corey A, additional, Hontz, Robert D, additional, Lin, Jin, additional, Beye, Matthew J, additional, Smith, Lauren, additional, Pan, Li, additional, Cheng, Ying, additional, Fox, Isabella, additional, Lizewski, Stephen E, additional, Foo, Hayley S, additional, Krebs, Shelly J, additional, Sun, Peifang, additional, and Letizia, Andrew G, additional

Published
2024
Full Text
View/download PDF

20. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

Author

Ober Shepherd, Brittany L, primary, Scott, Paul T, additional, Hutter, Jack N, additional, Lee, Christine, additional, McCauley, Melanie D, additional, Guzman, Ivelese, additional, Bryant, Christopher, additional, McGuire, Sarah, additional, Kennedy, Jessie, additional, Chen, Wei-Hung, additional, Hajduczki, Agnes, additional, Mdluli, Thembi, additional, Valencia-Ruiz, Anais, additional, Amare, Mihret F, additional, Matyas, Gary R, additional, Rao, Mangala, additional, Rolland, Morgane, additional, Mascola, John R, additional, De Rosa, Stephen C, additional, McElrath, M Juliana, additional, Montefiori, David C, additional, Serebryannyy, Leonid, additional, McDermott, Adrian B, additional, Peel, Sheila A, additional, Collins, Natalie D, additional, Joyce, M Gordon, additional, Robb, Merlin L, additional, Michael, Nelson L, additional, Vasan, Sandhya, additional, Modjarrad, Kayvon, additional, Gebrehana, Beza, additional, Greenleaf, Melissa E, additional, Hamer, Melinda J, additional, Jansen, Nathan K, additional, Jing, Xiaotang, additional, Kagai, Jael, additional, Kourbanova, Kamila, additional, Koren, Michael A, additional, Martin, Monica L, additional, Wuertz, Kathryn McGuckin, additional, Regules, Jason A, additional, Sanborn, Aaron D, additional, Wallace, David, additional, Zhu, Lei, additional, Gromowski, Gregory D, additional, Corbitt, Courtney, additional, Darden, Janice M, additional, Dussupt, Vincent, additional, Golub, Emily S, additional, Headley, Jarrett A, additional, Jarral, Umair M, additional, King, Jocelyn, additional, Krebs, Shelly J, additional, Lay, Jenny, additional, Lilly, Regina, additional, Lynch, Jennifer, additional, Martinez, Elizabeth J, additional, Mayer, Sandra V, additional, McGeehon, Samantha, additional, Lee, Hyunna, additional, Schech, Steven, additional, Tadesse, Mekdi, additional, Thomas, Paul V, additional, Romem, Yahel, additional, Zografos, Erifile, additional, Lin, Bob C, additional, Narpala, Sandeep R, additional, Wang, Lingshu, additional, Doria-Rose, Nicole A, additional, Carroll, Robin E, additional, Eaton, Amanda, additional, Badraslioglu, Emily D, additional, Koontz, Jason M, additional, Nwaeze, Ugo E, additional, Dawson, Peter, additional, Noll, Alexander J, additional, Orndahl, Christine M, additional, Bray, Amy, additional, Carrion, Ricardo, additional, Patterson, Jean, additional, Kulkarni, Viraj, additional, Hallam, Cory, additional, Gonzalez, Olga, additional, and Gazi, Michal, additional

Published
2024
Full Text
View/download PDF

21. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Author

Dussupt, Vincent, Sankhala, Rajeshwer S., Mendez-Rivera, Letzibeth, Townsley, Samantha M., Schmidt, Fabian, Wieczorek, Lindsay, Lal, Kerri G., Donofrio, Gina C., Tran, Ursula, Jackson, Nathaniel D., Zaky, Weam I., Zemil, Michelle, Tritsch, Sarah R., Chen, Wei-Hung, Martinez, Elizabeth J., Ahmed, Aslaa, Choe, Misook, Chang, William C., Hajduczki, Agnes, Jian, Ningbo, Peterson, Caroline E., Rees, Phyllis A., Rutkowska, Magdalena, Slike, Bonnie M., Selverian, Christopher N., Swafford, Isabella, Teng, I-Ting, Thomas, Paul V., Zhou, Tongqing, Smith, Clayton J., Currier, Jeffrey R., Kwong, Peter D., Rolland, Morgane, Davidson, Edgar, Doranz, Benjamin J., Mores, Christopher N., Hatziioannou, Theodora, Reiley, William W., Bieniasz, Paul D., Paquin-Proulx, Dominic, Gromowski, Gregory D., Polonis, Victoria R., Michael, Nelson L., Modjarrad, Kayvon, Joyce, M. Gordon, and Krebs, Shelly J.

Published
2021
Full Text
View/download PDF

22. Neurologic signs and symptoms frequently manifest in acute HIV infection.

Author

Hellmuth, Joanna, Fletcher, James LK, Valcour, Victor, Kroon, Eugène, Ananworanich, Jintanat, Intasan, Jintana, Lerdlum, Sukalaya, Narvid, Jared, Pothisri, Mantana, Allen, Isabel, Krebs, Shelly J, Slike, Bonnie, Prueksakaew, Peeriya, Jagodzinski, Linda L, Puttamaswin, Suwanna, Phanuphak, Nittaya, Spudich, Serena, and SEARCH 010/RV254 Study Group

Subjects
SEARCH 010/RV254 Study Group, Brain, Humans, HIV Infections, Acute Disease, Anti-Retroviral Agents, Magnetic Resonance Imaging, Severity of Illness Index, Incidence, Cohort Studies, Follow-Up Studies, Motor Activity, Cognition, Time Factors, Adult, Female, Male, Biomarkers, Mental Health, Pediatric, Clinical Research, HIV/AIDS, Neurosciences, Infectious Diseases, Infection, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo determine the incidence, timing, and severity of neurologic findings in acute HIV infection (pre-antibody seroconversion), as well as persistence with combination antiretroviral therapy (cART).MethodsParticipants identified with acute HIV were enrolled, underwent structured neurologic evaluations, immediately initiated cART, and were followed with neurologic evaluations at 4 and 12 weeks. Concurrent brain MRIs and both viral and inflammatory markers in plasma and CSF were obtained.ResultsMedian estimated HIV infection duration was 19 days (range 3-56) at study entry for the 139 participants evaluated. Seventy-three participants (53%) experienced one or more neurologic findings in the 12 weeks after diagnosis, with one developing a fulminant neurologic manifestation (Guillain-Barré syndrome). A total of 245 neurologic findings were noted, reflecting cognitive symptoms (33%), motor findings (34%), and neuropathy (11%). Nearly half of the neurologic findings (n = 121, 49%) occurred at diagnosis, prior to cART initiation, and most of these (n = 110, 90%) remitted concurrent with 1 month on treatment. Only 9% of neurologic findings (n = 22) persisted at 24 weeks on cART. Nearly all neurologic findings (n = 236, 96%) were categorized as mild in severity. No structural neuroimaging abnormalities were observed. Participants with neurologic findings had a higher mean plasma log10 HIV RNA at diagnosis compared to those without neurologic findings (5.9 vs 5.4; p = 0.006).ConclusionsAcute HIV infection is commonly associated with mild neurologic findings that largely remit while on treatment, and may be mediated by direct viral factors. Severe neurologic manifestations are infrequent in treated acute HIV.

Published
2016

23. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals

Author

Krebs, Shelly J, Slike, Bonnie M, Sithinamsuwan, Pasiri, Allen, Isabel E, Chalermchai, Thep, Tipsuk, Somporn, Phanuphak, Nittaya, Jagodzinski, Linda, Kim, Jerome H, Ananworanich, Jintanat, Marovich, Mary A, and Valcour, Victor G

Subjects
Pediatric AIDS, Neurosciences, HIV/AIDS, Behavioral and Social Science, Infectious Diseases, Clinical Research, Acquired Cognitive Impairment, Brain Disorders, Mental Health, Pediatric, Evaluation of treatments and therapeutic interventions, Aetiology, 6.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Infection, Adult, Anti-Retroviral Agents, Cerebrospinal Fluid, Enzyme-Linked Immunosorbent Assay, Female, HIV Infections, Humans, Immunologic Factors, Male, Middle Aged, Plasma, Sex Factors, Thailand, Young Adult, cognition, cytokines, HIV, neopterin, sCD14, sex, soluble factors, SEARCH 011 study team, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology
Abstract

ObjectiveTo evaluate differences in soluble inflammatory markers between chronically HIV-infected men and women, with or without cognitive impairment, and in response to treatment.DesignSoluble biomarkers were measured in cryopreserved plasma and cerebrospinal fluid (CSF) of 60 treatment-naïve individuals (25 men and 35 women) with chronic HIV infection and 18 HIV-uninfected controls (9 men and 9 women) from Thailand. Following enrollment, participants began combination antiretroviral therapy and were evaluated for expression of these markers after 48 weeks.MethodsPlasma and CSF levels of 19 soluble biomarkers (IFN-γ, TNFα, TNF-RII, IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-15, MCP-1, t-Tau, IP-10, neopterin, IFNα, I-FABP, and sCD14) were measured using either a multiparameter or standard ELISA assay.ResultsPrior to combination antiretroviral therapy, women with impaired cognition had elevated levels of neopterin and TNF-RII compared with women with normal cognition in both the plasma and CSF; however, levels did not differ between cognitively impaired or normal men. In a secondary outcome-hypothesis generating analysis, sex differences were also pronounced in plasma levels of MCP-1, IL-10, I-FABP, and sCD14 in response to treatment. Neopterin, IP-10, TNFα, TNF-RII, IFNα, MCP-1, IL-8, I-FABP, and sCD14 plasma levels remained elevated following 48 weeks of therapy in both sexes compared with uninfected controls.ConclusionWe provide evidence of sustained immune activation after 48 weeks of treatment and identify possible sex differences in biomarkers previously linked to cognitive impairment, chronic inflammation, and gut integrity that may contribute to immunological differences between sexes in relationship to disease progression and response to therapy.

Published
2016

24. Informing the need for a SARS-CoV-2 booster based upon the immune response among young, healthy adults to variants circulating during late 2023

Author

Nguyen, Huy C., primary, Lal, Kerri G., additional, Balinsky, Corey A., additional, Smith, Lauren, additional, Pan, Li, additional, Cheng, Ying, additional, Fox, Isabella, additional, Hontz, Robert D., additional, Lizewski, Stephen E., additional, Foo, Hayley S., additional, Krebs, Shelly J., additional, Sun, Peifang, additional, and Letizia, Andrew G., additional

Published
2023
Full Text
View/download PDF

25. Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States

Author

Wieczorek, Lindsay, primary, Sanders-Buell, Eric, additional, Zemil, Michelle, additional, Lewitus, Eric, additional, Kavusak, Erin, additional, Heller, Jonah, additional, Molnar, Sebastian, additional, Rao, Mekhala, additional, Smith, Gabriel, additional, Bose, Meera, additional, Nguyen, Amy, additional, Dhungana, Adwitiya, additional, Okada, Katherine, additional, Parisi, Kelly, additional, Silas, Daniel, additional, Slike, Bonnie, additional, Ganesan, Anuradha, additional, Okulicz, Jason, additional, Lalani, Tahaniyat, additional, Agan, Brian K., additional, Crowell, Trevor A., additional, Darden, Janice, additional, Rolland, Morgane, additional, Vasan, Sandhya, additional, Ake, Julie, additional, Krebs, Shelly J., additional, Peel, Sheila, additional, Tovanabutra, Sodsai, additional, and Polonis, Victoria R., additional

Published
2023
Full Text
View/download PDF

26. CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people living with HIV

Author

Albalawi, Yasmeen A., primary, Shull, Tanner, additional, Virdi, Amber, additional, Subra, Caroline, additional, Mitchell, Julie, additional, Slike, Bonnie M., additional, Jian, Ningbo, additional, Krebs, Shelly J., additional, Sacdalan, Carlo, additional, Ratnaratorn, Nisakorn, additional, Hsu, Denise C., additional, Phanuphak, Nittaya, additional, Spudich, Serena, additional, Trautmann, Lydie, additional, and Al-Harthi, Lena, additional

Published
2023
Full Text
View/download PDF

27. Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities

Author

RV254/SEARCH010, SEARCH011, and RV304/SEARCH013 Study Groups, D’Antoni, Michelle L., Byron, Mary Margaret, Chan, Phillip, Sailasuta, Napapon, Sacdalan, Carlo, Sithinamsuwan, Pasiri, Tipsuk, Somporn, Pinyakorn, Suteeraporn, Kroon, Eugene, Slike, Bonnie M., Krebs, Shelly J., Khadka, Vedbar S., Chalermchai, Thep, Kallianpur, Kalpana J., Robb, Merlin, Spudich, Serena, Valcour, Victor, Ananworanich, Jintanat, and Ndhlovu, Lishomwa C.

Published
2018

28. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

Author

Dussupt, Vincent, Sankhala, Rajeshwer S., Gromowski, Gregory D., Donofrio, Gina, De La Barrera, Rafael A., Larocca, Rafael A., Zaky, Weam, Mendez-Rivera, Letzibeth, Choe, Misook, Davidson, Edgar, McCracken, Michael K., Brien, James D., Abbink, Peter, Bai, Hongjun, Bryan, Aubrey L., Bias, Candace Hope, Berry, Irina Maljkovic, Botero, Nubia, Cook, Tanya, Doria-Rose, Nicole A., Escuer, Ariadna Grinyo i, Frimpong, Justice Akuoku, Geretz, Aviva, Hernandez, Mayda, Hollidge, Bradley S., Jian, Ningbo, Kabra, Kareem, Leggat, David J., Liu, Jinyan, Pinto, Amelia K., Rutvisuttinunt, Wiriya, Setliff, Ian, Tran, Ursula, Townsley, Samantha, Doranz, Benjamin J., Rolland, Morgane, McDermott, Adrian B., Georgiev, Ivelin S., Thomas, Rasmi, Robb, Merlin L., Eckels, Kenneth H., Barranco, Elizabeth, Koren, Michael, Smith, Darci R., Jarman, Richard G., George, Sarah L., Stephenson, Kathryn E., Barouch, Dan H., Modjarrad, Kayvon, Michael, Nelson L., Joyce, M. Gordon, and Krebs, Shelly J.

Published
2020
Full Text
View/download PDF

29. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research

Author

Wieczorek, Lindsay, Krebs, Shelly J, Kalyanaraman, Vaniambadi, Whitney, Stephen, Tovanabutra, Sodsai, Moscoso, Carlos G, Sanders-Buell, Eric, Williams, Constance, Slike, Bonnie, Molnar, Sebastian, Dussupt, Vincent, Alam, S Munir, Chenine, Agnes-Laurence, Tong, Tina, Hill, Edgar L, Liao, Hua-Xin, Hoelscher, Michael, Maboko, Leonard, Zolla-Pazner, Susan, Haynes, Barton F, Pensiero, Michael, McCutchan, Francine, Malek-Salehi, Shawyon, Cheng, R Holland, Robb, Merlin L, VanCott, Thomas, Michael, Nelson L, Marovich, Mary A, Alving, Carl R, Matyas, Gary R, Rao, Mangala, and Polonis, Victoria R

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related, Infectious Diseases, Biotechnology, Prevention, Immunization, Vaccine Related (AIDS), HIV/AIDS, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection, Good Health and Well Being, AIDS Vaccines, Animals, Drug Evaluation, Preclinical, HIV Antibodies, HIV Infections, HIV-1, Humans, Leukocytes, Mononuclear, Molecular Sequence Data, Neutralization Tests, Rabbits, Vaccination, env Gene Products, Human Immunodeficiency Virus, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

UnlabelledEliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected "fan blade" motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of cross-subtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine.ImportanceAt present, the product pipeline for HIV vaccines is insufficient and is limited by inadequate capacity to produce large quantities of vaccine to standards required for human clinical trials. Such products are required to evaluate critical questions of vaccine formulation, route, dosing, and schedule, as well as to establish vaccine efficacy. The gp145 Env protein presented in this study forms physical trimers, binds to many of the well-characterized broad neutralizing MAbs that target conserved Env epitopes, and induce cross-subtype neutralizing antibodies as measured in both cell line and primary cell assays. This subtype C Env gp145 protein is currently undergoing good manufacturing practice production for use as a reagent for preclinical studies and for human clinical research. This product will serve as a reagent for comparative studies and may represent a next-generation candidate HIV immunogen.

Published
2015

30. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

Author

Ake, Julie A., Akapirat, Siriwat, Bose, Meera, Cale, Evan, Chan, Phillip, Chanthaburanun, Sararut, Churikanont, Nampueng, Dawson, Peter, Dumrongpisutikul, Netsiri, Getchalarat, Saowanit, Jongrakthaitae, Surat, Jongsakul, Krisada, Lerdlum, Sukalaya, Manasnayakorn, Sopark, McCullough, Corinne, Milazzo, Mark, Nuntapinit, Bessara, On, Kier, Ouellette, Madelaine, Phanuphak, Praphan, Sanders-Buell, Eric, Sangnoi, Nongluck, Shangguan, Shida, Sirivichayakul, Sunee, Tragonlugsana, Nipattra, Trichavaroj, Rapee, Ubolyam, Sasiwimol, Vasan, Sandhya, Wattanaboonyongcharoen, Phandee, Yamchuenpong, Thipvadee, Crowell, Trevor A, Colby, Donn J, Pinyakorn, Suteeraporn, Sacdalan, Carlo, Pagliuzza, Amélie, Intasan, Jintana, Benjapornpong, Khunthalee, Tangnaree, Kamonkan, Chomchey, Nitiya, Kroon, Eugène, de Souza, Mark S, Tovanabutra, Sodsai, Rolland, Morgane, Eller, Michael A, Paquin-Proulx, Dominic, Bolton, Diane L, Tokarev, Andrey, Thomas, Rasmi, Takata, Hiroshi, Trautmann, Lydie, Krebs, Shelly J, Modjarrad, Kayvon, McDermott, Adrian B, Bailer, Robert T, Doria-Rose, Nicole, Patel, Bijal, Gorelick, Robert J, Fullmer, Brandie A, Schuetz, Alexandra, Grandin, Pornsuk V, O'Connell, Robert J, Ledgerwood, Julie E, Graham, Barney S, Tressler, Randall, Mascola, John R, Chomont, Nicolas, Michael, Nelson L, Robb, Merlin L, Phanuphak, Nittaya, and Ananworanich, Jintanat

Published
2019
Full Text
View/download PDF

32. Distinct mucosal and systemic immunological characteristics in transgender women potentially relating to HIV acquisition

Author

Schuetz, Alexandra, primary, Corley, Michael J., additional, Sacdalan, Carlo, additional, Phuang-Ngern, Yuwadee, additional, Nakpor, Thitiyanun, additional, Wansom, Tanyaporn, additional, Ehrenberg, Philip K., additional, Sriplienchan, Somchai, additional, Thomas, Rasmi, additional, Ratnaratorn, Nisakorn, additional, Sukhumvittaya, Suchada, additional, Tragonlugsana, Nipattra, additional, Slike, Bonnie M., additional, Akapirat, Siriwat, additional, Pinyakorn, Suteeraporn, additional, Rerknimitr, Rungsun, additional, Pang, Alina P.S., additional, Kroon, Eugène, additional, Teeratakulpisan, Nipat, additional, Krebs, Shelly J., additional, Phanuphak, Nittaya, additional, Ndhlovu, Lishomwa C., additional, and Vasan, Sandhya, additional

Published
2023
Full Text
View/download PDF

33. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity

Author

Jensen, Jaime L., primary, Sankhala, Rajeshwer S., additional, Dussupt, Vincent, additional, Bai, Hongjun, additional, Hajduczki, Agnes, additional, Lal, Kerri G., additional, Chang, William C., additional, Martinez, Elizabeth J., additional, Peterson, Caroline E., additional, Golub, Emily S., additional, Rees, Phyllis A., additional, Mendez-Rivera, Letzibeth, additional, Zemil, Michelle, additional, Kavusak, Erin, additional, Mayer, Sandra V., additional, Wieczorek, Lindsay, additional, Kannan, Shruthi, additional, Doranz, Benjamin J., additional, Davidson, Edgar, additional, Yang, Eun Sung, additional, Zhang, Yi, additional, Chen, Man, additional, Choe, Misook, additional, Wang, Lingshu, additional, Gromowski, Gregory D., additional, Koup, Richard A., additional, Michael, Nelson L., additional, Polonis, Victoria R., additional, Rolland, Morgane, additional, Modjarrad, Kayvon, additional, Krebs, Shelly J., additional, and Joyce, M. Gordon, additional

Published
2023
Full Text
View/download PDF

34. Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments

Author

RV254/SEARCH010 Study Group, Crowell, Trevor A., Colby, Donn J., Pinyakorn, Suteeraporn, Fletcher, James L. K., Kroon, Eugène, Schuetz, Alexandra, Krebs, Shelly J., Slike, Bonnie M., Leyre, Louise, Chomont, Nicolas, Jagodzinski, Linda L., Sereti, Irini, Utay, Netanya S., Dewar, Robin, Rerknimitr, Rungsun, Chomchey, Nitiya, Trichavaroj, Rapee, Valcour, Victor G., Spudich, Serena, Michael, Nelson L., Robb, Merlin L., Phanuphak, Nittaya, and Ananworanich, Jintanat

Published
2018

35. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection

Author

RV254/SEARCH 010, RV304/SEARCH 013 and SEARCH 011 protocol teams, Sereti, Irini, Krebs, Shelly J., Phanuphak, Nittaya, Fletcher, James L., Slike, Bonnie, Pinyakorn, Suteeraporn, O'Connell, Robert J., Rupert, Adam, Chomont, Nicolas, Valcour, Victor, Kim, Jerome H., Robb, Merlin L., Michael, Nelson L., Douek, Daniel C., Ananworanich, Jintanat, and Utay, Netanya S.

Published
2017

39. Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters

Author

King, Hannah A. D., primary, Dussupt, Vincent, additional, Mendez-Rivera, Letzibeth, additional, Slike, Bonnie M., additional, Tran, Ursula, additional, Jackson, Nathan D., additional, Barkei, Erica, additional, Zemil, Michelle, additional, Tourtellott-Fogt, Emily, additional, Kuklis, Caitlin H., additional, Soman, Sandrine, additional, Ahmed, Aslaa, additional, Porto, Maciel, additional, Kitajewski, Christopher, additional, Spence, Brittany, additional, Benetiene, Dalia, additional, Wieczorek, Lindsay, additional, Kar, Swagata, additional, Gromowski, Gregory, additional, Polonis, Victoria R., additional, Krebs, Shelly J., additional, Modjarrad, Kayvon, additional, and Bolton, Diane L., additional

Published
2023
Full Text
View/download PDF

40. Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies

Author

Kuriakose Gift, Syna, primary, Wieczorek, Lindsay, additional, Sanders-Buell, Eric, additional, Zemil, Michelle, additional, Molnar, Sebastian, additional, Donofrio, Gina, additional, Townsley, Samantha, additional, Chenine, Agnes L., additional, Bose, Meera, additional, Trinh, Hung V., additional, Barrows, Brittani M., additional, Sriplienchan, Somchai, additional, Kitsiripornchai, Suchai, additional, Nitayapan, Sorachai, additional, Eller, Leigh-Anne, additional, Rao, Mangala, additional, Ferrari, Guido, additional, Michael, Nelson L., additional, Ake, Julie A., additional, Krebs, Shelly J., additional, Robb, Merlin L., additional, Tovanabutra, Sodsai, additional, and Polonis, Victoria R., additional

Published
2023
Full Text
View/download PDF

41. Fc receptor engagement of HIV-1 Env-specific antibodies in mothers and infants predicts reduced vertical transmission

Author

Barrows, Brittani M., primary, Krebs, Shelly J., additional, Jian, Ningbo, additional, Zemil, Michelle, additional, Slike, Bonnie M., additional, Dussupt, Vincent, additional, Tran, Ursula, additional, Mendez-Rivera, Letzibeth, additional, Chang, David, additional, O’Sullivan, Anne Marie, additional, Mann, Brendan, additional, Sanders-Buell, Eric, additional, Shubin, Zhanna, additional, Creegan, Matt, additional, Paquin-Proulx, Dominic, additional, Ehrenberg, Philip, additional, Laurence-Chenine, Agnes, additional, Srithanaviboonchai, Kriengkrai, additional, Thomas, Rasmi, additional, Eller, Michael A., additional, Ferrari, Guido, additional, Robb, Merlin, additional, Rao, Venigalla, additional, Tovanabutra, Sodsai, additional, Polonis, Victoria R., additional, and Wieczorek, Lindsay, additional

Published
2022
Full Text
View/download PDF

45. HIV-1 infections with multiple founders associate with the development of neutralization breadth

Author

Lewitus, Eric, primary, Townsley, Samantha M., additional, Li, Yifan, additional, Donofrio, Gina C., additional, Dearlove, Bethany L., additional, Bai, Hongjun, additional, Sanders-Buell, Eric, additional, O’Sullivan, Anne Marie, additional, Bose, Meera, additional, Kibuuka, Hannah, additional, Maganga, Lucas, additional, Nitayaphan, Sorachai, additional, Sawe, Fredrick K., additional, Eller, Leigh Anne, additional, Michael, Nelson L., additional, Polonis, Victoria R., additional, Ake, Julie A., additional, Vasan, Sandhya, additional, Robb, Merlin L., additional, Tovanabutra, Sodsai, additional, Krebs, Shelly J., additional, and Rolland, Morgane, additional

Published
2022
Full Text
View/download PDF

46. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

Author

Joyce, M. Gordon, primary, King, Hannah A. D., additional, Elakhal-Naouar, Ines, additional, Ahmed, Aslaa, additional, Peachman, Kristina K., additional, Macedo Cincotta, Camila, additional, Subra, Caroline, additional, Chen, Rita E., additional, Thomas, Paul V., additional, Chen, Wei-Hung, additional, Sankhala, Rajeshwer S., additional, Hajduczki, Agnes, additional, Martinez, Elizabeth J., additional, Peterson, Caroline E., additional, Chang, William C., additional, Choe, Misook, additional, Smith, Clayton, additional, Lee, Parker J., additional, Headley, Jarrett A., additional, Taddese, Mekdi G., additional, Elyard, Hanne A., additional, Cook, Anthony, additional, Anderson, Alexander, additional, McGuckin Wuertz, Kathryn, additional, Dong, Ming, additional, Swafford, Isabella, additional, Case, James Brett, additional, Currier, Jeffrey R., additional, Lal, Kerri G., additional, Molnar, Sebastian, additional, Nair, Manoj S., additional, Dussupt, Vincent, additional, Daye, Sharon P., additional, Zeng, Xiankun, additional, Barkei, Erica K., additional, Staples, Hilary M., additional, Alfson, Kendra, additional, Carrion, Ricardo, additional, Krebs, Shelly J., additional, Paquin-Proulx, Dominic, additional, Karasavva, Nicos, additional, Polonis, Victoria R., additional, Jagodzinski, Linda L., additional, Amare, Mihret F., additional, Vasan, Sandhya, additional, Scott, Paul T., additional, Huang, Yaoxing, additional, Ho, David D., additional, de Val, Natalia, additional, Diamond, Michael S., additional, Lewis, Mark G., additional, Rao, Mangala, additional, Matyas, Gary R., additional, Gromowski, Gregory D., additional, Peel, Sheila A., additional, Michael, Nelson L., additional, Bolton, Diane L., additional, and Modjarrad, Kayvon, additional

Published
2022
Full Text
View/download PDF

47. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

Author

Joyce, M. Gordon, primary, Chen, Wei-Hung, additional, Sankhala, Rajeshwer S., additional, Hajduczki, Agnes, additional, Thomas, Paul V., additional, Choe, Misook, additional, Martinez, Elizabeth J., additional, Chang, William C., additional, Peterson, Caroline E., additional, Morrison, Elaine B., additional, Smith, Clayton, additional, Chen, Rita E., additional, Ahmed, Aslaa, additional, Wieczorek, Lindsay, additional, Anderson, Alexander, additional, Case, James Brett, additional, Li, Yifan, additional, Oertel, Therese, additional, Rosado, Lorean, additional, Ganesh, Akshaya, additional, Whalen, Connor, additional, Carmen, Joshua M., additional, Mendez-Rivera, Letzibeth, additional, Karch, Christopher P., additional, Gohain, Neelakshi, additional, Villar, Zuzana, additional, McCurdy, David, additional, Beck, Zoltan, additional, Kim, Jiae, additional, Shrivastava, Shikha, additional, Jobe, Ousman, additional, Dussupt, Vincent, additional, Molnar, Sebastian, additional, Tran, Ursula, additional, Kannadka, Chandrika B., additional, Soman, Sandrine, additional, Kuklis, Caitlin, additional, Zemil, Michelle, additional, Khanh, Htet, additional, Wu, Weimin, additional, Cole, Matthew A., additional, Duso, Debra K., additional, Kummer, Larry W., additional, Lang, Tricia J., additional, Muncil, Shania E., additional, Currier, Jeffrey R., additional, Krebs, Shelly J., additional, Polonis, Victoria R., additional, Rajan, Saravanan, additional, McTamney, Patrick M., additional, Esser, Mark T., additional, Reiley, William W., additional, Rolland, Morgane, additional, de Val, Natalia, additional, Diamond, Michael S., additional, Gromowski, Gregory D., additional, Matyas, Gary R., additional, Rao, Mangala, additional, Michael, Nelson L., additional, and Modjarrad, Kayvon, additional

Published
2021
Full Text
View/download PDF

48. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

Author

Wuertz, Kathryn McGuckin, primary, Barkei, Erica K., additional, Chen, Wei-Hung, additional, Martinez, Elizabeth J., additional, Lakhal-Naouar, Ines, additional, Jagodzinski, Linda L., additional, Paquin-Proulx, Dominic, additional, Gromowski, Gregory D., additional, Swafford, Isabella, additional, Ganesh, Akshaya, additional, Dong, Ming, additional, Zeng, Xiankun, additional, Thomas, Paul V., additional, Sankhala, Rajeshwer S., additional, Hajduczki, Agnes, additional, Peterson, Caroline E., additional, Kuklis, Caitlin, additional, Soman, Sandrine, additional, Wieczorek, Lindsay, additional, Zemil, Michelle, additional, Anderson, Alexander, additional, Darden, Janice, additional, Hernandez, Heather, additional, Grove, Hannah, additional, Dussupt, Vincent, additional, Hack, Holly, additional, de la Barrera, Rafael, additional, Zarling, Stasya, additional, Wood, James F., additional, Froude, Jeffrey W., additional, Gagne, Matthew, additional, Henry, Amy R., additional, Mokhtari, Elham Bayat, additional, Mudvari, Prakriti, additional, Krebs, Shelly J., additional, Pekosz, Andrew S., additional, Currier, Jeffrey R., additional, Kar, Swagata, additional, Porto, Maciel, additional, Winn, Adrienne, additional, Radzyminski, Kamil, additional, Lewis, Mark G., additional, Vasan, Sandhya, additional, Suthar, Mehul, additional, Polonis, Victoria R., additional, Matyas, Gary R., additional, Boritz, Eli A., additional, Douek, Daniel C., additional, Seder, Robert A., additional, Daye, Sharon P., additional, Rao, Mangala, additional, Peel, Sheila A., additional, Joyce, M. Gordon, additional, Bolton, Diane L., additional, Michael, Nelson L., additional, and Modjarrad, Kayvon, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results